These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 22846040)

  • 1. Insights into the inhibition of the p90 ribosomal S6 kinase (RSK) by the flavonol glycoside SL0101 from the 1.5 Å crystal structure of the N-terminal domain of RSK2 with bound inhibitor.
    Utepbergenov D; Derewenda U; Olekhnovich N; Szukalska G; Banerjee B; Hilinski MK; Lannigan DA; Stukenberg PT; Derewenda ZS
    Biochemistry; 2012 Aug; 51(33):6499-510. PubMed ID: 22846040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of quercitrin as an inhibitor of the p90 S6 ribosomal kinase (RSK): structure of its complex with the N-terminal domain of RSK2 at 1.8 Å resolution.
    Derewenda U; Artamonov M; Szukalska G; Utepbergenov D; Olekhnovich N; Parikh HI; Kellogg GE; Somlyo AV; Derewenda ZS
    Acta Crystallogr D Biol Crystallogr; 2013 Feb; 69(Pt 2):266-75. PubMed ID: 23385462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identifying requirements for RSK2 specific inhibitors.
    Wright EB; Fukuda S; Li M; Li Y; O'Doherty GA; Lannigan DA
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1798-1809. PubMed ID: 34348556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of the first specific inhibitor of p90 ribosomal S6 kinase (RSK) reveals an unexpected role for RSK in cancer cell proliferation.
    Smith JA; Poteet-Smith CE; Xu Y; Errington TM; Hecht SM; Lannigan DA
    Cancer Res; 2005 Feb; 65(3):1027-34. PubMed ID: 15705904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of rhamnose substituents on the potency of SL0101, an inhibitor of the Ser/Thr kinase, RSK.
    Smith JA; Maloney DJ; Clark DE; Xu Y; Hecht SM; Lannigan DA
    Bioorg Med Chem; 2006 Sep; 14(17):6034-42. PubMed ID: 16723233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two widely used RSK inhibitors, BI-D1870 and SL0101, alter mTORC1 signaling in a RSK-independent manner.
    Roffé M; Lupinacci FC; Soares LC; Hajj GN; Martins VR
    Cell Signal; 2015 Aug; 27(8):1630-42. PubMed ID: 25889895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis of a potent and selective inhibitor of p90 Rsk.
    Maloney DJ; Hecht SM
    Org Lett; 2005 Mar; 7(6):1097-9. PubMed ID: 15760148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells.
    Stratford AL; Fry CJ; Desilets C; Davies AH; Cho YY; Li Y; Dong Z; Berquin IM; Roux PP; Dunn SE
    Breast Cancer Res; 2008; 10(6):R99. PubMed ID: 19036157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analogs of the RSK inhibitor SL0101: optimization of in vitro biological stability.
    Hilinski MK; Mrozowski RM; Clark DE; Lannigan DA
    Bioorg Med Chem Lett; 2012 May; 22(9):3244-7. PubMed ID: 22464132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural basis for the activity of the RSK-specific inhibitor, SL0101.
    Smith JA; Maloney DJ; Hecht SM; Lannigan DA
    Bioorg Med Chem; 2007 Jul; 15(14):5018-34. PubMed ID: 17512736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regioselective Synthesis of a
    Li Y; Sandusky ZM; Vemula R; Zhang Q; Wu B; Fukuda S; Li M; Lannigan DA; O'Doherty GA
    Org Lett; 2020 Feb; 22(4):1448-1452. PubMed ID: 32009414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Divergent off-target effects of RSK N-terminal and C-terminal kinase inhibitors in cardiac myocytes.
    Stathopoulou K; Schobesberger S; Bork NI; Sprenger JU; Perera RK; Sotoud H; Geertz B; David JP; Christ T; Nikolaev VO; Cuello F
    Cell Signal; 2019 Nov; 63():109362. PubMed ID: 31344438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The unusual mechanism of inhibition of the p90 ribosomal S6 kinase (RSK) by flavonol rhamnosides.
    Utepbergenov D; Derewenda ZS
    Biochim Biophys Acta; 2013 Jul; 1834(7):1285-91. PubMed ID: 23541530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting p90 ribosomal S6 kinase eliminates tumor-initiating cells by inactivating Y-box binding protein-1 in triple-negative breast cancers.
    Stratford AL; Reipas K; Hu K; Fotovati A; Brough R; Frankum J; Takhar M; Watson P; Ashworth A; Lord CJ; Lasham A; Print CG; Dunn SE
    Stem Cells; 2012 Jul; 30(7):1338-48. PubMed ID: 22674792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Homology model of RSK2 N-terminal kinase domain, structure-based identification of novel RSK2 inhibitors, and preliminary common pharmacophore.
    Nguyen TL; Gussio R; Smith JA; Lannigan DA; Hecht SM; Scudiero DA; Shoemaker RH; Zaharevitz DW
    Bioorg Med Chem; 2006 Sep; 14(17):6097-105. PubMed ID: 16723234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The p90 ribosomal S6 kinase (RSK) inhibitor BI-D1870 prevents gamma irradiation-induced apoptosis and mediates senescence via RSK- and p53-independent accumulation of p21WAF1/CIP1.
    Neise D; Sohn D; Stefanski A; Goto H; Inagaki M; Wesselborg S; Budach W; Stühler K; Jänicke RU
    Cell Death Dis; 2013 Oct; 4(10):e859. PubMed ID: 24136223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural basis for activation of the autoinhibitory C-terminal kinase domain of p90 RSK2.
    Malakhova M; Tereshko V; Lee SY; Yao K; Cho YY; Bode A; Dong Z
    Nat Struct Mol Biol; 2008 Jan; 15(1):112-3. PubMed ID: 18084304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving the affinity of SL0101 for RSK using structure-based design.
    Mrozowski RM; Vemula R; Wu B; Zhang Q; Schroeder BR; Hilinski MK; Clark DE; Hecht SM; O'Doherty GA; Lannigan DA
    ACS Med Chem Lett; 2012 Feb; 4(2):175-179. PubMed ID: 23519677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of RSK/YB-1 signaling enhances the anti-cancer effect of enzalutamide in prostate cancer.
    Shiota M; Yokomizo A; Takeuchi A; Itsumi M; Imada K; Kashiwagi E; Inokuchi J; Tatsugami K; Uchiumi T; Naito S
    Prostate; 2014 Jun; 74(9):959-69. PubMed ID: 24740858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel potent and selective inhibitors of p90 ribosomal S6 kinase reveal the heterogeneity of RSK function in MAPK-driven cancers.
    Aronchik I; Appleton BA; Basham SE; Crawford K; Del Rosario M; Doyle LV; Estacio WF; Lan J; Lindvall MK; Luu CA; Ornelas E; Venetsanakos E; Shafer CM; Jefferson AB
    Mol Cancer Res; 2014 May; 12(5):803-12. PubMed ID: 24554780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.